title: New drugs in development for the treatment of endometriosis.
abstract: Endometriosis is a common and enigmatic disease causing pelvic pain and infertility. Current treatment is mainly based on the use of surgery and ovarian suppressive agents. There is in particular the need for new therapeutic options able to allow a normal menstrual cycle to occur and also consent pregnancy. In the present review, we aimed to give a concise and practical overview in order to allow the clinician to clearly understand the level of development of these drugs. We have presented only treatments supported by in vivo researches with a special attention to studies in humans. Results show appealing new possibilities are emerging from agents counteracting the endometriosis-associated inflammation. Recent data also suggests that there is still the opportunity to refine the use of already available agents.
authors.affiliation: Fondazione IRCCS Ospedale Maggiore Policlinico, Obstetrics and Gynecology, Mangiagalli e Regina Elena, Via Commenda 12, 20122 Milano, Italy. luigi.fedele@unimi.it
authors.forename: Luigi
authors.initials: L
authors.lastname: Fedele
authors.forename: Edgardo
authors.initials: E
authors.lastname: Somigliana
authors.forename: Giada
authors.initials: G
authors.lastname: Frontino
authors.forename: Laura
authors.initials: L
authors.lastname: Benaglia
authors.forename: Paola
authors.initials: P
authors.lastname: Vigano
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015195:Drug Design; D004715:Endometriosis / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D005260:Female; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D047495:PPAR gamma / Q000819:agonists; D011960:Receptors, Estrogen / Q000819:agonists; D011980:Receptors, Progesterone / Q000819:agonists; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D047072:Aromatase Inhibitors; D006727:Hormone Antagonists; D047495:PPAR gamma; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D014409:Tumor Necrosis Factor-alpha